Amgen, Inc.

Blinatumomab added to chemotherapy significantly improves 3-year disease-free survival in children with B-cell acute lymphoblastic leukemia, reducing the hazard ratio for disease recurrence by 61%.

Adding BLINCYTO® (blinatumomab) to chemotherapy significantly improves disease-free survival (DFS) in newly diagnosed pediatric patients with National Cancer Institute (NCI) standard risk B-cell acute lymphoblastic leukemia (B-ALL), with a 3-year DFS of 96%.

Adding BLINCYTO to chemotherapy significantly improves disease-free survival in pediatric patients with B-cell acute lymphoblastic leukemia, with a 3-year DFS of 96% compared to 87.9% with chemotherapy alone.

Adding BLINCYTO (blinatumomab) to chemotherapy significantly improves disease-free survival (DFS) in newly diagnosed pediatric patients with B-cell acute lymphoblastic leukemia (B-ALL), with a 3-year DFS of 96% compared to 87.9% with chemotherapy alone.

Amgen's Phase 3 study shows BLINCYTO plus chemotherapy significantly improves 3-year disease-free survival (DFS) in pediatric NCI standard risk B-cell acute lymphoblastic leukemia (B-ALL) patients, with 96.0% DFS in BLINCYTO group vs. 87.9% in chemotherapy-only group, and a 61% reduction in risk of relapse. Safety profile consistent with known BLINCYTO risks.

Blinatumomab plus chemotherapy significantly improved 3-year disease-free survival rates and was well tolerated in pediatric patients with standard-risk B-ALL, reducing bone marrow relapse rates and showing no significant increase in severe adverse effects.

BioAge Labs halts mid-stage study of obesity drug azelaprag due to safety concerns, causing a 75% share price drop. Elevated liver enzyme levels in participants receiving azelaprag, either alone or with Eli Lilly's tirzepatide, led to the decision. BioAge plans to update on azelaprag's development in early 2025.

Eli Lilly's tirzepatide (Mounjaro, Zepbound) dominates the weight loss market, generating billions in sales. Competing with Novo Nordisk, Lilly's Zepbound showed superior weight loss results in studies, positioning it to potentially surpass Novo Nordisk's sales by 2025. However, challenges from compounding pharmacies and supply issues pose risks.

Amgen's Phase 3 study shows BLINCYTO plus chemotherapy significantly improves 3-year disease-free survival (DFS) in pediatric NCI SR B-ALL patients, with 96.0% DFS vs. 87.9% with chemotherapy alone, and a 61% reduction in relapse risk.